Tuesday marked the start of the world’s first phase III clinical trial of a COVID-19 inactivated vaccine, and an Abu Dhabi AI and cloud computing firm teamed up with a Chinese National Biotec Group to make it happen. 

Sinopharm CNBG inactivated vaccine already passed phases I and II clinical trials without showing any serious adverse reactions, with 100% of the volunteers generating antibodies after two doses in 28 days, according to a report via Wam.ae.

A ceremony was held via video call to mark the announcement

Recommended

The UAE Has NOT Had A COVID-19 Related Death For Well Over A MonthThose Who Come Into Contact With COVID-19 Positive Cases Must Do A PCR Test On Day 1 & 7BREAKING: Non-Vaccinated Tourists Can Now Enter Events & Attractions In Abu Dhabi

The clinical trial process is usually divided into three phases

The first phase mainly looks into the safety of the vaccine.

Phase II evaluates immunogenicity and explores the immunization process in a limited number of individuals.

Phase III considers the safety and effectiveness of the vaccine in a larger population sample. If a vaccine is confirmed safe and effective throughout the entire clinical trial process, the test is considered successful, and the vaccine enters into the large-scale manufacturing phase.

This is the CLOSEST a vaccine has come to reaching approval in the world and if approved, the vaccine could enter the market by the end of 2020 or early 2021

LISTEN: Dubai Schools WILL Reopen In September 

Apple Podcasts / Google Podcasts / Anghami